Meeting
2023 ASCO Annual Meeting
Association of accelerated approval (AA) status with National Comprehensive Cancer Network (NCCN) guideline recommendation for cancer drug indications: A cross-sectional study.
Authors
Edward Robert Scheffer Cliff
Program on Regulation, Therapeutics and Law, Boston, MA
Edward Robert Scheffer Cliff , Rachel S Rome , Aaron S Kesselheim , Benjamin N Rome
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Care Delivery and Regulatory Policy
Track
Care Delivery and Quality Care
Sub Track
Health and Regulatory Policy
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 1599)
DOI
10.1200/JCO.2023.41.16_suppl.1599
Abstract #
1599
Poster Bd #
193
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Clinical practice guideline descriptions of oncologic drugs granted FDA accelerated approval: A cross-sectional study.
First Author: Maryam Mooghali
Poster
2020 ASCO Virtual Scientific Program
Factors associated with change in the magnitude of clinical benefit of anti-cancer drugs in the post-marketing period.
First Author: Aida Bujosa Rodríguez
First Author: Samer El Kababji
Poster
2023 ASCO Genitourinary Cancers Symposium
Cross-sectional study of patients' (pts) and physicians' needs and the financial toxicity of systemic treatment for metastatic renal cell carcinoma (mRCC) in Japan.
First Author: Takahiro Osawa